Reactivities against p75 (MS vs PD: 6.7 vs 28.6%, p = 0.037), p41 (MS vs PD: 25 vs 71.4%, p = 0.003), p30-OMP (MS vs PD: 11.7 vs 50%, p = 0.001), p29-UreA (MS vs PD: 45 vs 85.7%, p = 0.007) and p26 (MS vs PD: 51.7 vs 85.7%, p = 0.033) were less frequent in MS than PD. This evidence concerns the gene OMP and myeloid sarcoma.